Next Article in Journal
Successful Intrathecal Chemotherapy Combined with Radiotherapy Followed by Pomalidomide and Low-Dose Dexamethasone Maintenance Therapy for a Primary Plasma Cell Leukemia Patient
Previous Article in Journal
Successful Treatment of Immune Reconstitution Inflammatory Syndrome-Related Hemophagocytic Syndrome in an HIV Patient with Primary Effusion Lymphoma
 
 
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Efficacy of Colchicine and Dapsone Combination Therapy in Relapsed Immune Thrombocytopenia

by
Thanawat Rattanathammethee
,
Wasan Theerajangkhaphichai
,
Ekarat Rattarittamrong
*,
Sasinee Hantrakool
,
Chatree Chai-Adisaksopha
,
Lalita Norasetthada
and
Adisak Tantiworawit
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, 110 Intravaroros Road, A. Muang, Chiang Mai 50200, Thailand
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2017, 9(1), 22-27; https://doi.org/10.4081/hr.2017.7034
Submission received: 9 January 2017 / Revised: 26 January 2017 / Accepted: 5 February 2017 / Published: 23 February 2017

Abstract

The aim of the present paper is to evaluate the efficacy and safety of colchicine and dapsone combination therapy in cases of steroid-dependent, relapsed and refractory immune thrombocytopenia (ITP). This is a retrospective study of ITP patients who attended the Hematology Clinic at Chiang Mai University Hospital (Thailand) from 1 January 2008 to 30 September 2014. Medical records and clinical data were reviewed for efficacy and adverse effects. Sixty-four ITP patients received the combination therapy. The median age was 46 years and 70.3% were female. The majority (65.6%) were relapsed ITP patients. Median platelet count before starting treatment was 22.6 × 109/L. The response rate was 82.8%, with 75.0% of patients having a complete response. Median time to response was 8 weeks. The response rate was higher in relapsed patients (90.4%) compared to refractory (61.5%) and steroid-dependent patients (77.8%). Steroid treatment was discontinued in 30 patients (50%) following combination therapy. The most common side effect was hemolysis due to dapsone which was found in eight patients (12.5%). We can therefore conclude that combination therapy with colchicine and dapsone is an alternative second-line therapy option in relapsed ITP cases with acceptable side effects.
Keywords: relapsed immune thrombocytopenia; colchicine; dapsone relapsed immune thrombocytopenia; colchicine; dapsone

Share and Cite

MDPI and ACS Style

Rattanathammethee, T.; Theerajangkhaphichai, W.; Rattarittamrong, E.; Hantrakool, S.; Chai-Adisaksopha, C.; Norasetthada, L.; Tantiworawit, A. The Efficacy of Colchicine and Dapsone Combination Therapy in Relapsed Immune Thrombocytopenia. Hematol. Rep. 2017, 9, 22-27. https://doi.org/10.4081/hr.2017.7034

AMA Style

Rattanathammethee T, Theerajangkhaphichai W, Rattarittamrong E, Hantrakool S, Chai-Adisaksopha C, Norasetthada L, Tantiworawit A. The Efficacy of Colchicine and Dapsone Combination Therapy in Relapsed Immune Thrombocytopenia. Hematology Reports. 2017; 9(1):22-27. https://doi.org/10.4081/hr.2017.7034

Chicago/Turabian Style

Rattanathammethee, Thanawat, Wasan Theerajangkhaphichai, Ekarat Rattarittamrong, Sasinee Hantrakool, Chatree Chai-Adisaksopha, Lalita Norasetthada, and Adisak Tantiworawit. 2017. "The Efficacy of Colchicine and Dapsone Combination Therapy in Relapsed Immune Thrombocytopenia" Hematology Reports 9, no. 1: 22-27. https://doi.org/10.4081/hr.2017.7034

APA Style

Rattanathammethee, T., Theerajangkhaphichai, W., Rattarittamrong, E., Hantrakool, S., Chai-Adisaksopha, C., Norasetthada, L., & Tantiworawit, A. (2017). The Efficacy of Colchicine and Dapsone Combination Therapy in Relapsed Immune Thrombocytopenia. Hematology Reports, 9(1), 22-27. https://doi.org/10.4081/hr.2017.7034

Article Metrics

Back to TopTop